First US Part III trial for COVID-19 vaccine begins

Image of a woman in a lab coat holding scientific instruments.

Enlarge / A analysis affiliate works on the Moderna Therapeutics Inc. lab in Cambridge, Massachusetts. (credit score: Bloomberg/Getty Photographs)

Moderna has given the primary doses of its experimental COVID-19 vaccine to contributors in what shall be a 30,000-person trial, as the US moved into a brand new part of the race to develop a vaccine by the beginning of subsequent yr.

The Boston-based biotech stated on Monday that it had begun the primary Part III research of a vaccine within the US, a large-scale trial that’s normally the final earlier than a brand new product is submitted for regulatory approval.

The corporate’s shares have been up as a lot as 10.6 p.c earlier than paring a few of their positive factors.

Learn 11 remaining paragraphs | Feedback

Related Posts

Leave a Reply

Your email address will not be published.